4-(4-氯苯氧基)哌啶 | 97839-99-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(4-氯苯氧基)哌啶
• 中文别名: 4-4-氯苯氧基哌啶
• 英文名称: 4-(4-chlorophenoxy)-piperidine
• 英文别名: 4-(4-Chlorophenoxy)piperidine
• CAS: 97839-99-1
• 化学式: C₁₁H₁₄ClNO
• mdl: MFCD04113544
• 分子量: 211.691
• InChiKey: VOQMPZXAFLPTMM-UHFFFAOYSA-N

物化性质

• 沸点：
  312.8±32.0 °C(Predicted)
• 密度：
  1.150±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  常温常压下稳定，避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(4-氯苯氧基)哌啶 在 氢氧化钾 、 TEA 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 4.0h， 生成 [4-(4-Chloro-phenoxy)-piperidin-1-yl]-oxo-acetic acid
  参考文献：
  名称：

  Oxamides as novel NR2B selective NMDA receptor antagonists

  摘要：

  A novel series of oxamides derived from indole-2-carboxamides was identified as potent NR2B selective NMDA receptor antagonists. Several members of this group showed good analgesic activity in the mouse formalin test. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.053
• 作为产物：
  描述：

  4-氯吡啶 在 palladium on activated charcoal sodium tetrahydroborate 、 氢气 、 1-(4-吡啶基)吡啶氯盐酸盐 作用下， 以 甲醇 、 乙醚 、 乙醇 为溶剂， 反应 54.0h， 生成 4-(4-氯苯氧基)哌啶
  参考文献：
  名称：

  Oxamides as novel NR2B selective NMDA receptor antagonists

  摘要：

  A novel series of oxamides derived from indole-2-carboxamides was identified as potent NR2B selective NMDA receptor antagonists. Several members of this group showed good analgesic activity in the mouse formalin test. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.053

文献信息

• DIPHENYL DERIVATIVES AND USES THEREOF
  申请人：NOVARTIS AG

  公开号：US20190077773A1

  公开（公告）日：2019-03-14

  The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

  本公开提供了一种公式(I)的化合物： 或其药用可接受的盐，以及其用于激活生长因子途径、促进伤口愈合、促进组织修复以及治疗听力损失、骨骼肌损失、器官退化、组织损伤、神经退化和肌肉萎缩的治疗用途。本公开还提供了药物组合物和组合物。本公开还涉及将此类化合物用于研究或其他非治疗目的。
• [EN] ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE EN TANT QU'INHIBITEURS DE CANAL SODIQUE POUR LE TRAITEMENT DE LA DOULEUR
  申请人：AMGEN INC

  公开号：WO2011103196A1

  公开（公告）日：2011-08-25

  The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了一种抑制电压门控钠通道（Nav）的化合物，特别是Nav 1.7，因此适用于治疗通过抑制这些通道可治疗的疾病，特别是慢性疼痛疾病。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017011776A1

  公开（公告）日：2017-01-19

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• PHTHALAZINONE DERIVATIVES
  申请人：MENEAR Keith Allan

  公开号：US20090192156A1

  公开（公告）日：2009-07-30

  A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; R C is selected from H, C 1-4 alkyl; and R 1 is selected from C 1-7 alkyl, C 3-20 heterocyclyl and C 5-20 aryl, which groups are optionally substituted; or R C and R 1 together with the carbon and oxygen atoms to which they are attached form a spiro-C 5-7 oxygen-containing heterocyclic group, which is optionally substituted or fused to a C 5-7 aromatic ring.

  其中： A和B一起代表一个可选取代的融合芳香环；X和Y分别从CH和CH、CF和CH、CH和CF以及N和CH中选择；RC从H、C1-4烷基中选择；R1从C1-7烷基、C3-20杂环烷基和C5-20芳基中选择，这些基团可选取代；或者RC和R1与它们连接的碳和氧原子一起形成一个可选取代或与C5-7芳香环融合的螺环C5-7含氧杂环基。
• NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS
  申请人：KHAMRAI Uttam

  公开号：US20100168080A1

  公开（公告）日：2010-07-01

  The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

  本发明涉及作为CC趋化因子受体，如CCR1的配体的新型吗啉、恶唑烷和哌啶衍生物。该发明还涉及制备这些化合物的方法、包含这些化合物的组合物以及使用这些化合物的治疗方法。